The purpose of this study was to evaluate the efficacy and safety of danaparoid in the treatment of critically ill patients with acute renal failure and suspected heparin-induced thrombocytopenia (HIT) needing renal replacement therapy (RRT). We conducted a retrospective analysis of 13 consecutive intensive care patients with acute renal failure and suspected HIT who were treated with danaparoid for at least 3 days during RRT. In eight patients, continuous venovenous hemofiltration was performed. The mean infusion rate of danaparoid was 140 &plusmn; 86 U/hour. Filter exchange was necessary every 37.5 hours. In five patients, continuous venovenous hemodialysis was used. A bolus injection of 750 U danaparoid was followed by a mean infusion rate of 138 &plusmn; 122 U/hour. Filters were exchanged every 24 hours. In 7 of 13 patients, even a low mean infusion rate of 88 & p l u s m n ; 35 U/hour was efficient. Mean anti-Xa (aXa) levels were approximately 0.4 & p l u s m n ; 0.2 aXa U/mL. Persistent thrombocytopenia despite discontinuation of heparin treatment was observed in 9 of 13 patients, owing to disseminated intravascular coagulation (DIC). HIT was confirmed by an increase in platelet count and positive heparin-induced antibodies in 2 of 13 patients. No thromboembolic complications occurred, but major bleeding was observed in 6 of 13 patients, which could be explained by consumption of coagulation factors and platelets due to DIC in 5 of 6 patients. Nine of 13 patients died of multiorgan failure or sepsis, or both. In none of these patients was the fatal outcome related to danaparoid treatment. In critically ill patients with renal impairment and suspected HIT, a bralus injection of 750 U danaparoid followed by a mean infusion rate of 50 to 150 U/hour appears to be a safe and efficient treatment option when alternative anticoagutation is necessary.
Summary: The purpose of this study was to evaluate the efficacy and safety of danaparoid in the treatment of critically ill patients with acute renal failure and suspected heparin-induced thrombocytopenia (HIT) needing renal replacement therapy (RRT) . We conducted a retrospective analysis of 13 consecutive intensive care patients with acute renal failure and suspected HIT who were treated with danaparoid for at least 3 days during RRT. In eight patients, continuous venovenous hemofiltration was performed. The mean infusion rate of danaparoid was 140 &plusmn; 86 U/hour. Filter exchange was necessary every 37.5 hours. In five patients, continuous venovenous hemodialysis was used. A bolus injection of 750 U danaparoid was followed by a mean infusion rate of 138 &plusmn; 122 U/hour. Filters were exchanged every 24 hours. In 7 of 13 patients, even a low mean infusion rate of 88 & p l u s m n ; 35 U/hour was efficient. Mean anti-Xa (aXa) levels were approximately 0.4 & p l u s m n ; 0.2 aXa U/mL. Persistent thrombocytopenia despite discontinuation of heparin treatment was observed in 9 of 13 patients, owing to disseminated intravascular coagulation (DIC) . HIT was confirmed by an increase in platelet count and positive heparin-induced antibodies in 2 of 13 patients. No thromboembolic complications occurred, but major bleeding was observed in 6 of 13 patients, which could be explained by consumption of coagulation factors and platelets due to DIC in 5 of 6 patients. Nine of 13 patients died of multiorgan failure or sepsis, or both. In none of these patients was the fatal outcome related to danaparoid treatment. In critically ill patients with renal impairment and suspected HIT, a bralus injection of 750 U danaparoid followed by a mean infusion rate of 50 to 150 U/hour appears to be a safe and efficient treatment option when alternative anticoagutation is necessary. Key Words: Low-molecular-weight hepari-noid&mdash;Danaparoid&mdash;Renal insufficiency-Renal replacement therapy&mdash;Intensive care. Acute renal failure occurs frequently in critically ill patients and commonly occurs with other organ system failures Because intermittent renal replacement therapy and peritoneal dialysis have some limitations in efficacy and clinical tolerance (2), continuous renal replacement therapy is increasingly being used because of the steady biochemical correction, slow continuous fluid removal, and excellent cardiovascular stability (3) . Mortality among critically ill patients is high and varies between 40 and 80% (4). Usually, unfractionated heparin (UFH) is used for anticoagulation to avoid clotting within the extracorporai circuits. A serious, rare, but lifethreatening side effect of treatment with UFH is the immune form of heparin-induced thrombocytopenia (HIT). The incidence of HIT differs depending on the patient population studied and can affect ~:9~1~ of patients who start with hemodialysis because of impaired renal function (5) . However, no HIT was observed in 166 patients on chronic, intermittent hemodialysis (6) . In patients with suspected HIT, heparin treatment should be discontinued and alternative anticoagulation should be started with either r-himdin or a low-molecular-weight heparinoid (danaparoid) (7) . While renal elimination of danaparoid is 45%, renal elimination of r-hirudin is 95%. Therefore, in patients with acute renal failure, the TI/2 of danaparoid is only prolonged from 24 to 31 hours ~~~, ' whereas with r-hirudin a prolongation from 1 to 52 hours i is observed, depending on the residual renal function. I This may lead to drug accumulation, and close laboratory i monitoring is recommended (9) . In cases of suspected HIT, danaparoid may therefore have an increased thera-/ peutic window in patients with acute renal failure as ; compared with r-hirudin. A single bolus injection of danaparoid is a useful and safe alternative anticoagulant dur-/ ing hemodialysis (10) (11) (12) (13) , while only limited data about application in venovenous hemofiltration in critically ill ' patients are available (14) .
Danaparoid has been used for years as an anticoagulant in patients with proven or suspected at our -enter. We therefore administered this to critically ill patients suspected HIT during continuous renal replacement therapy. A retrospective, clinical evaluation of these patients was performed.
METHODS .

Patients
Between July 1998 and November 2000, 3 consecudve intensive care patients (9 men, 4 women, age: 62 ± 10 years) with suspected HIT required venovenous renal replacement therapy with alternative anticoagulation because of acute renal failure. Only patients treated with danaparoid for a minimum of 3 days were included in the ' : retrospective analysis of clinical data. HIT was suspected when thrombocytopenia developed during treatment with UFH and alternative causes for thrombocytopenia were less likely. Laboratory testing for heparin-induced mtibodies included a heparin-platelet factor 4-antibodyassay (HPIA, Stage, Paris, France) (15) or a functional ; assay (heparin-induced platelet activation assay), or both ' (16) . In vitro cross-reactivity of danaparoid with heparininduced antibodies was excluded in all patients. The clinical and biologic findings were retrospectively re-' viewed.
. The majority of patients (n= 10) presented with sepsis, and all patients had multiple organ failure. . Table I shows the data of the patients at inclusion.
& d q u o ;
Anticoagulation with danaparoid j When HIT was suspected, treatment with UFH ! (Liquemin, Hoffmann-La Roche, Grenzach-Wyhlen, ! Germany) was stopped and danaparoid (Orgaran, Thie-mann Arzneimittel, Waltrop, Germany) was started intravenously. The danaparoid dosage was adapted to each patient's individual situation and targeted to protect the patient from clot formation.,
Monitoring of anticoagulation with danaparoid
Monitoring of anticoagulation was performed by repeated measurement of anti-Xa (aXa) activity using a standard curve, established with control plasma containing danaparoid sodium dilutions (chromogenic substrate: S 2222, Haemochrom Diagnostics, Essen, Germany). Monitoring of platelet count, creatinine, prothrombin time, activated partial thromboplastin time, and antithrombin activity was performed every day.
Procedure of continuous venovenous renal .
replacement therapy
In patients in the surgical intensive care unit, continuous venovenous hemofiltration (CVVH) was performed (n = 8), while in the medical intensive care unit patients were treated with continuous venovenous hemodialysis (CVVHD, n = 5). Renal replacement therapy was performed using polysulfone high-flux hemofilter (Polysulfon F50, Fresenius, Bad Homburg, Germany, and PSH 1200, Baxter, Unter-schleit3heim, Germany). A BM !!-!4 dialysis machine (Baxter, Llntersc:l~leit~l~eim, Germany) wars used for CV-VHD. A bicarbonate solution was used either as a dialysate or hemofiltration solution. The flow rate in both procedures was between I and 4 L/hour, depending on the clinical situation. The blood flow was 100 to 200 mL/minute. The ultrafiltration rate depended on each patient's need. Priming of the system was performed with l ;~~(l U of danaparoid. An intravenous bolus of danaparoid was applied in eight patients (Tables 2 and 3) ; maintenance infusion was then adapted to each patient's individual situation. While the hemofilter system was automatically changed every 24 hours in all patients treated with CVVHD, in patients treated with CVVH the filter system was only changed when occlusion off the filter occurred.
Occurrence of bleeding
Major bleeding was defined as the occurrence off bleeding. requiring transfusion, active intervention, or cessation of anticoagutation. ' 
RESULTS
Renal r~p~tac~ra°t~n~ therapy
In eight patients continuous venovenous hemofiltration (CVVH) was performed because of acute renal failure. In three patients a bolus of 2,250 U danaparoid was applied at start of treatment. Sixty-nine hemofiltration were performed, and filter exchange was necessary every 37.5 hours on average ( Table 2 ). The mean infusion rate of danaparoid was I~f~ + 86 U/hour. The mean aXa level measured during continuous venous application of danaparoid was 0.45 + ~.°~3 aXa U/mL. Five patients were anuric at the initiation of danaparoid treatment, and three patients had residual diuresis. The amount of danaparoid required to keep the filter open was not different between diuretic and anuric patients. No adaptation of dosage was necessary when renal function improved.
In five patients, CVVHD was used for treatment of acute renal insufficiency ( 
Patient outcomes
Persistent thrombocytopenia despite interruption of heparin treatment was observed in nine patients, due to sepsis and disseminated intravas;ular coagulation (DIC). In five patients heparin-induced antibodies were positive in at least one assay, while in the remaining eight patients negative antibody results were observed in both assays. In two of the five patients with positive antibody results the platelet count increased after stop of heparin and start of danaparoid treatment, whereas in the three other patients the platelet count remained low after change of anticoagulant treatment. Disseminated intravascular coagulation was more likely to be responsible for thrombocytopenia in these patients. Therefore, HIT was confirmed by an increase in platelet count and positive heparin-induced antibodies in only 2 of 1~ patients. 
Bleeding
Major bleeding complications were observed in six patients: three patients (patient 6, patient 10, and patient 12) developed bleeding from tracheostoma, in two of these patients interruption of danaparoid treatment was necessary, while in one patient Mood transfusions were administered. In two patients danaparoid treatment was restarted without further complications.
One patient (patient 3) developed a hemorrhagic pleural effusion after drainage of spontaneous pneumothorax. After interruption of the danaparoid infusion for day and administration of blood transfusions, the bleeding stopped and danaparoid treatment could be continued without further complications. A second patient (patient 5) also developed a hemorrhagic effusion after implani tation of a pacemaker. After interruption of danaparoid treatment for I day the bteeding stopped and danaparoid could be restarted.
In another patient (patient 9) bleeding from surgical _ wounds after amputation of both lower legs occurred. Amputation had been necessary because of acute arterial occlusion due to antiphospholipid-antibody syndrome and periarteritis nodosa. After administrations of blood & d q u o ;
) transfusions no further bleeding occurred, although dan-. aparoid treatment had not been interrupted. In two of six . patients with bleeding complications, invasive proce-° j dures such as tracheostomy were performed without . interruption of danaparoid treatment, while in five of j six patients sepsis and DIC were present when the bleeding occurred. Danaparoid levels were within the thera-&dquo; peutic or prophylactic range in all patients with bleedj ing complications.
DISCUSSION '
In patients with acute renal failure treated with renal ! replacement therapy, anticoagulation with heparin is nec-&dquo; essary to keep hemofilters patent. Most of these patients also have sepsis and DIC, which cause thrombocytopenia and consumption of coagulation factors, leading to hemorrhagic complications. Therefore, treatment of this pal tient population remains a challenge, especially because the knowledge about HIT has increased and HIT often is discussed as differential diagnosis when thrombocytope-! nia occurs on the intensive care unit.
Depending on the patient population studied, 7.5 to 50% of patients treated with heparin develop heparininduced antibodies using an enzyme-linked immunosorbent assay, while only 2 to 34.5% of these develop the clinical picture of HIT ( I'~), Therefore, the specificity of the laboratory assays appears to be low, especially in intensive care patients, in whom thrombocytopenia often occurs because of DIC. In our patient population, HIT was confirmed by an increase in platelet count after interruption of heparin treatment in only 2 of 13 patients with suspected HIT, although 5 of 13 patients had presented with heparin-induced antibodies. Therefore, it is questionable whether laboratory testing for heparin-induced antibodies is useful in intensive care patients. When HIT is suspected, immediate cessation of heparin treatment and a change to an alternative anticoagulation is mandatory (7) , although experience with hirudin or danaparoid in this difficult clinical situation is still low. In our study of critically ill intensive care patients with acute renal failure and suspected HIT, anticoagulation was performed with danaparoid. Two different regimens for renal replacement therapy were used: either CVVHD with filter exchange every 24 hours or CVVH with change of filter systems on demand. With both regimens no difference in mean maintenance do;age off danaparoid or aXa levels in plasma were observed. When hirudin is used for anticoagulation during renal replacement therapy, a higher dosage of hirudin may be required during hemofiltration as compared with hemodialysis because the high molecular weight of hirudin impairs diffusion (18) . A body weight-independent dosage was possible using danaparoid.
The mean maintenance dosage of danaparoid was between 50 and 150 aXa U/hour in the majority of patients with mean aXa levels of approximately 0.4 U/mL. This infusion rate is lower than the dosage recommended in the literature (after a bolus injection of 2,000 to 2,500 U, a step-down infusion schedule of 600 aXa U/hour for 4 hours, 400 aXa U/hour for 4 hours, and maintenance infusion of 200 to 600 aXa U/hour) (19) .
In our study, a bolus injection was administered to 8 of 13 patients. A bolus injection of I ampule of danaparoid (750 U) may be enough as loading dose and might cause fewer filter exchanges in the beginning of therapy. A step-down schedule bolus injection, as recommended, might not be necessary according to our results (19, 20) . Although dose adjustments of hirudin with close monitoring are necessary when renal clearance increases (18) , no dose adjustment was necessary when renal function recovered in our patients. This can be explained by the decreased renal elimination rate of danaparoid (45%) (8) as compared with hirudin (95%) (9) . Although the danaparoid infusion rate was quite low in most of the patients treated with CVVH and most of them required catecholamines because of low blood pressure, the average duration of filter patency was 37.5 hours. The good performance of danaparoid in keeping hemofilters open may be explained by the fact that the platelet proaggregating and potentiating effects of this heparinoid are much lower when compared with unfractionated or low-molecular-weight heparin in intensive care patients. Therefore= accelerated clot formation occurring on dialysis membranes in intensive care patients undergoing venovenous hemodialysis with UFH resolves with replacement by danaparoid ~~ l ). No thromboembolic complications occurred in this patient population, but the bleeding tendency was high (6 of 1 ~ patients), even though the aXa levels were within either the prophylactic or low therapeutic range. This may have been caused by consumption of coagulation factors and platelets due to DIC and sepsis in five of six patients. In another retrospective analysis of 42 consecutive critically ill patients without multiple organ failure and renal replacement therapy treated with danaparoid, bleeding complications only occurred in 2 patients who were additionally treated with aspirin (22) . Therefore, the high bleeding tendency in our patients is possibly related to the underlying DIC and not related to danaparoid,. According to our experience, most bleeding complications can be avoided when the danaparoid infusion is interrupted for at least 6 hours before planned invasive procedures such as tracheotomy are performed.
In summary, danaparoid appears to be a safe and efficient treatment option when alternative anticoagulation is necessary in critically ill patients with renal impairment and suspected HIT.
